The effects of recombinant human IL-7 as an adjuvant in augmenting the number of tumor-infiltrating T cells, specific antitumor immune responses, and survival time of tumor-bearing models also have been revealed in other published studies (84–86). The gene discussed is IL7; the disease is neoplasm.